OncoMatch/Clinical Trials/NCT07300683
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
Is NCT07300683 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CARCCR9 T cells for t cell acute lymphoblastic leukemia.
Treatment: CARCCR9 T cells — The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory. * be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells. * be given the CAR T cells into their vein. * stay in the hospital for a minimum of 2 weeks to be closely monitored * following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years) * during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and/or imaging tests (CT/PET-CT scans) depending on their type of T-cell cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CCR9 positive disease as assessed by flow cytometry
CCR9-positive disease as assessed by flow cytometry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: combination cytotoxic chemotherapy
Relapsed or refractory T-ALL/T-LBL following at least one (≥18 years old) or two (<18 years old) standard prior lines of combination cytotoxic therapy
Lab requirements
Kidney function
gfr <30 ml/min
Liver function
bilirubin >3 x upper limit of normal
Cardiac function
cardiac dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07300683 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received combination cytotoxic chemotherapy.
Does this trial require CCR9?
Yes, CCR9 positive disease as assessed by flow cytometry is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify